作者
Steven E Nissen, Taro Tsunoda, E Murat Tuzcu, Paul Schoenhagen, Christopher J Cooper, Muhammad Yasin, Gregory M Eaton, Michael A Lauer, W Scott Sheldon, Cindy L Grines, Stephen Halpern, Tim Crowe, James C Blankenship, Richard Kerensky
发表日期
2003/11/5
期刊
Jama
卷号
290
期号
17
页码范围
2292-2300
出版商
American Medical Association
简介
Context
Although low levels of high-density lipoprotein cholesterol (HDL-C) increase risk for coronary disease, no data exist regarding potential benefits of administration of HDL-C or an HDL mimetic. ApoA-I Milano is a variant of apolipoprotein A-I identified in individuals in rural Italy who exhibit very low levels of HDL. Infusion of recombinant ApoA-I Milano–phospholipid complexes produces rapid regression of atherosclerosis in animal models.
Objective
We assessed the effect of intravenous recombinant ApoA-I Milano/phospholipid complexes (ETC-216) on atheroma burden in patients with acute coronary syndromes (ACS).
Design
The study was a double-blind, randomized, placebo-controlled multicenter pilot trial comparing the effect of ETC-216 or placebo on coronary atheroma burden measured by intravascular ultrasound (IVUS).
Setting
Ten community and tertiary care hospitals in the United States.
Patients …
引用总数
学术搜索中的文章
SE Nissen, T Tsunoda, EM Tuzcu, P Schoenhagen… - Jama, 2003